Corporate News
Kondor Pharma publishes results of a clinical trial on Alzheimer’s disease patients treated with K-Vie™ Boswellia extract
Clinical study shows benefit of Kondor Pharma's proprietary boswellia extract, K-Vie™, on cognitive function in patients with traumatic brain injury
MISSISSAUGA, Ontario (April 11, 2022) – Kondor Pharma Inc. is pleased to announce the publication of its clinical trial investigating the efficacy of K-Vie™, a proprietary extract of Boswellia serrata, on cognitive function in patients with traumatic brain injury (TBI). The study was published in the peer-reviewed journal, Brain Injury, 2022 Apr 6; 1-7, and is titled: Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injury.
Kondor Pharma publishes results of a clinical study on COVID-19 patients treated with Inflawell®, a proprietary immune support formulation
MISSISSAUGA, Ontario (February 28, 2022) – Kondor Pharma Inc. is pleased to announce the publication of its clinical trial results on moderate COVID-19 patients which demonstrates the efficacy of Inflawell®, its recently developed K-Vie™-based immune support formulation. The study has been published online (ahead of print) in the peer-reviewed journal, Inflammopharmacology, 2022 Feb 24; 1-11, and is titled, Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial (2022 Feb 24;1-11).
Kondor Pharma launches newly enhanced e-commerce website capabilities
To make online shopping easier for its digitally savvy customers, Kondor Pharma has invested in a new e-commerce shop on its consumer-facing website.
Through the enhanced shop page, visitors can seamlessly browse products, read in-depth product descriptions, and experience a quick and convenient checkout process.
Memowell, Genuwell, and Strowell now available on Amazon in Canada and the U.S.
Company Announcement | October 27, 2021
Kondor Pharma is pleased to announce that our products are now available on Amazon.com (U.S.) and Amazon.ca (Canada). This will provide shoppers with more flexibility in ordering with a fast and user-friendly purchasing experience.
New website launch for Kondor Pharma
Company Announcement | August 19, 2021
Kondor Pharma is pleased to announce the launch of a new consumer website. The new site has a refreshed navigation, brand identity, and educational pages to help consumers learn more about the link between inflammation and adverse health conditions.
Kondor Pharma wins Johnson & Johnson Next in Natural Quickfire Challenge on immune support
We are proud to announce that Kondor Pharma has been selected a winner of the Johnson & Johnson Next in Natural Quickfire Challenge on immune support.
Kondor Pharma focuses on high-quality herbal ingredients with a long history of use in traditional medicine in ancient cultures. A strong immune system provides an effective defense against harmful germs, substances, and antigens. The herbal ingredients used by Kondor Pharma have robust antioxidant and immunomodulatory effects and result in improvement of immune support, as shown in multiple studies.
The selection of Kondor Pharma as a winner of this competition by the Johnson & Johnson QuickFire challenge review panel further speaks to the quality and novelty of our strategy.
Kondor Pharma publishes results of a clinical study on COVID-19 patients treated with Inflawell®, a proprietary immune support formulation
PRESS RELEASE | February 28, 2022
MISSISSAUGA, Ontario (February 28, 2022) – Kondor Pharma Inc. is pleased to announce the publication of its clinical trial results on moderate COVID-19 patients which demonstrates the efficacy of Inflawell®, its recently developed K-Vie™-based immune support formulation. The study has been published online (ahead of print) in the peer-reviewed journal, Inflammopharmacology, 2022 Feb 24; 1-11, and is titled, Inflawell® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial (2022 Feb 24;1-11).
